vs
Hagerty, Inc.（HGTY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Hagerty, Inc.的2.0倍（$772.1M vs $388.1M），Revvity净利率更高（12.7% vs 7.4%，领先5.4%），Hagerty, Inc.同比增速更快（16.5% vs 5.9%），Hagerty, Inc.自由现金流更多（$194.5M vs $161.8M），过去两年Hagerty, Inc.的营收复合增速更高（19.5% vs 9.0%）
哈格蒂（Hagerty, Inc.）是美国知名汽车生活方式及会员服务企业，同时是全球规模最大的经典老爷车特种保险供应商，总部位于密歇根州特拉弗斯城，业务范围覆盖加拿大、德国及英国市场。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HGTY vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$388.1M
营收增速更快
HGTY
高出10.6%
5.9%
净利率更高
RVTY
高出5.4%
7.4%
自由现金流更多
HGTY
多$32.7M
$161.8M
两年增速更快
HGTY
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $388.1M | $772.1M |
| 净利润 | $28.6M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 10.2% | 14.5% |
| 净利率 | 7.4% | 12.7% |
| 营收同比 | 16.5% | 5.9% |
| 净利润同比 | 238.4% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HGTYRVTY
| Q4 25 | $388.1M | $772.1M | ||
| Q3 25 | $380.0M | $698.9M | ||
| Q2 25 | $368.7M | $720.3M | ||
| Q1 25 | $319.6M | $664.8M | ||
| Q4 24 | $333.2M | $729.4M | ||
| Q3 24 | $323.4M | $684.0M | ||
| Q2 24 | $313.2M | $691.7M | ||
| Q1 24 | $271.7M | $649.9M |
净利润HGTYRVTY
| Q4 25 | $28.6M | $98.4M | ||
| Q3 25 | $46.2M | $46.7M | ||
| Q2 25 | $47.2M | $53.9M | ||
| Q1 25 | $27.3M | $42.2M | ||
| Q4 24 | $8.4M | $94.6M | ||
| Q3 24 | $19.0M | $94.4M | ||
| Q2 24 | $42.7M | $55.4M | ||
| Q1 24 | $8.2M | $26.0M |
毛利率HGTYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率HGTYRVTY
| Q4 25 | 10.2% | 14.5% | ||
| Q3 25 | 9.0% | 11.7% | ||
| Q2 25 | 12.9% | 12.6% | ||
| Q1 25 | 8.1% | 10.9% | ||
| Q4 24 | 1.8% | 16.3% | ||
| Q3 24 | 3.1% | 14.3% | ||
| Q2 24 | 12.2% | 12.4% | ||
| Q1 24 | 4.5% | 6.8% |
净利率HGTYRVTY
| Q4 25 | 7.4% | 12.7% | ||
| Q3 25 | 12.2% | 6.7% | ||
| Q2 25 | 12.8% | 7.5% | ||
| Q1 25 | 8.5% | 6.4% | ||
| Q4 24 | 2.5% | 13.0% | ||
| Q3 24 | 5.9% | 13.8% | ||
| Q2 24 | 13.6% | 8.0% | ||
| Q1 24 | 3.0% | 4.0% |
每股收益（稀释后）HGTYRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $160.2M | $919.9M |
| 总债务越低越好 | $177.9M | — |
| 股东权益账面价值 | $221.3M | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资HGTYRVTY
| Q4 25 | $160.2M | $919.9M | ||
| Q3 25 | $290.5M | $931.4M | ||
| Q2 25 | $259.6M | $991.8M | ||
| Q1 25 | $232.7M | $1.1B | ||
| Q4 24 | $178.7M | $1.2B | ||
| Q3 24 | $208.9M | $1.2B | ||
| Q2 24 | $186.4M | $2.0B | ||
| Q1 24 | $131.2M | $1.7B |
总债务HGTYRVTY
| Q4 25 | $177.9M | — | ||
| Q3 25 | $104.4M | — | ||
| Q2 25 | $153.4M | — | ||
| Q1 25 | $132.6M | — | ||
| Q4 24 | $105.8M | — | ||
| Q3 24 | $122.9M | — | ||
| Q2 24 | $98.0M | — | ||
| Q1 24 | $91.5M | — |
股东权益HGTYRVTY
| Q4 25 | $221.3M | $7.3B | ||
| Q3 25 | $211.7M | $7.4B | ||
| Q2 25 | $172.3M | $7.6B | ||
| Q1 25 | $162.9M | $7.6B | ||
| Q4 24 | $150.3M | $7.7B | ||
| Q3 24 | $148.3M | $7.9B | ||
| Q2 24 | $94.4M | $7.9B | ||
| Q1 24 | $93.5M | $7.8B |
总资产HGTYRVTY
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.2B | $12.1B | ||
| Q2 25 | $2.0B | $12.4B | ||
| Q1 25 | $1.8B | $12.4B | ||
| Q4 24 | $1.7B | $12.4B | ||
| Q3 24 | $1.8B | $12.8B | ||
| Q2 24 | $1.7B | $13.4B | ||
| Q1 24 | $1.6B | $13.4B |
负债/权益比HGTYRVTY
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 1.04× | — | ||
| Q1 24 | 0.98× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $219.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $194.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 50.1% | 21.0% |
| 资本支出强度资本支出/营收 | 6.3% | 2.6% |
| 现金转化率经营现金流/净利润 | 7.67× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $365.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HGTYRVTY
| Q4 25 | $219.0M | $182.0M | ||
| Q3 25 | $92.2M | $138.5M | ||
| Q2 25 | $53.9M | $134.3M | ||
| Q1 25 | $43.8M | $128.2M | ||
| Q4 24 | $177.0M | $174.2M | ||
| Q3 24 | $67.4M | $147.9M | ||
| Q2 24 | $64.0M | $158.6M | ||
| Q1 24 | $58.2M | $147.6M |
自由现金流HGTYRVTY
| Q4 25 | $194.5M | $161.8M | ||
| Q3 25 | $85.2M | $120.0M | ||
| Q2 25 | $47.7M | $115.5M | ||
| Q1 25 | $38.4M | $112.2M | ||
| Q4 24 | $155.7M | $149.8M | ||
| Q3 24 | $62.0M | $125.6M | ||
| Q2 24 | $56.6M | $136.6M | ||
| Q1 24 | $53.7M | $129.7M |
自由现金流率HGTYRVTY
| Q4 25 | 50.1% | 21.0% | ||
| Q3 25 | 22.4% | 17.2% | ||
| Q2 25 | 12.9% | 16.0% | ||
| Q1 25 | 12.0% | 16.9% | ||
| Q4 24 | 46.7% | 20.5% | ||
| Q3 24 | 19.2% | 18.4% | ||
| Q2 24 | 18.1% | 19.7% | ||
| Q1 24 | 19.8% | 20.0% |
资本支出强度HGTYRVTY
| Q4 25 | 6.3% | 2.6% | ||
| Q3 25 | 1.8% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 6.4% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% | ||
| Q1 24 | 1.7% | 2.7% |
现金转化率HGTYRVTY
| Q4 25 | 7.67× | 1.85× | ||
| Q3 25 | 2.00× | 2.97× | ||
| Q2 25 | 1.14× | 2.49× | ||
| Q1 25 | 1.61× | 3.03× | ||
| Q4 24 | 20.97× | 1.84× | ||
| Q3 24 | 3.55× | 1.57× | ||
| Q2 24 | 1.50× | 2.87× | ||
| Q1 24 | 7.10× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HGTY
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
